Fredun Pharmaceuticals Ltd
NSE: BSE: 539730
₹1678.55
(-0.73%)
Sun, 15 Mar 2026, 07:14 am
Market Cap9.07B
PE Ratio24.25
Dividend0.04
Health Technology
Pharmaceuticals: Major
24.5KFredun Pharmaceuticals Analysis
dividend
- Fredun Pharmaceuticals is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Fredun Pharmaceuticals's dividends as it is not paying a notable one for India.
- Fredun Pharmaceuticals is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Fredun Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.75%).
- Fredun Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.09%).
health
- Fredun Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Fredun Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Fredun Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 3.3x debt.
- Fredun Pharmaceuticals's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (243.1% vs 70.3% today).
- Operating cash flow is negative therefore debt is not well covered.
- Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
- Fredun Pharmaceuticals's level of debt (70.3%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Fredun Pharmaceuticals board of directors is about average.
- Daulat's remuneration is lower than average for companies of similar size in India.
- Daulat's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Fredun Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Fredun Pharmaceuticals is not covered by any analysts.
- Fredun Pharmaceuticals has significant price volatility in the past 3 months.
past
- Fredun Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
- Fredun Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Fredun Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Fredun Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Fredun Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Fredun Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- BSE:539730 is up 12.8% outperforming the Pharmaceuticals industry which returned 6.2% over the past month.
- BSE:539730 is up 12.8% outperforming the market in India which returned 9% over the past month.
- Fredun Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Fredun Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Fredun Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Fredun Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Fredun Pharmaceuticals is overvalued based on earnings compared to the India market.
- 539730 underperformed the Pharmaceuticals industry which returned 24.6% over the past year.
- 539730 underperformed the Market in India which returned -14.8% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800